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Best and Brightest Forum on Medical Innovation
Franklin Institute, Philadelphia, Pennsylvania
December 15, 2008
On December 15, 2008, former Congressman
Dick Gephardt facilitated a program that featured
keynote speaker Governor Edward G. Rendell
to discuss the future of medical innovation in
the United States. The discussion focused, in
particular, on the greater Philadelphia area in
the context of the current economic downturn.
In addition to the keynote, two expert panels
highlighted obstacles to innovation as well as
potential solutions. Panelists included:
•D
 ennis M. “Mickey” Flynn, President of
Pennsylvania BIO
•G
 len N. Gaulton, PhD, Executive Vice Dean,
Chief Scientific Officer at The University of
Pennsylvania School of Medicine
•B
 renda Gavin, DVM, MBA, Founding Partner
of Quaker BioVentures
•P
 aul Howard, PhD, Senior Fellow and Director
of the Center for Medical Progress at the
Manhattan Institute for Policy Research
•R
 ussel Kaufman, MD, President and CEO of
the Wistar Institute
•A
 lan Leshner, PhD, CEO of the American
Association for the Advancement of Science
References

• J oseph M. Mahady, President of Wyeth
Pharmaceuticals and Senior Vice President
at Wyeth
•T
 homas Morr, President and CEO of Select
Greater Philadelphia
•D
 avid B. Nash, MD, MBA, Dean of the
Jefferson School of Population Health at
Thomas Jefferson University
•B
 arbara S. Schilberg, Managing Director and
Chief Executive Officer of BioAdvance
•T
 he Honorable Joe Sestak (D-PA), U.S. House
of Representatives
•G
 eorge Wohlreich, MD, Director and CEO of
the College of Physicians of Philadelphia
The Greater Philadelphia area is a hub for medical
innovation activities, with a strong biotechnology
sector and numerous academic institutions
with nationally recognized programs in the
life sciences. According to a 2005 Milken
Institute study1, the medical innovation industry
in Greater Philadelphia encompasses 11.4 percent
of all employment in the region, 12.8 percent
of total earnings, and 7.1 percent of gross
metro product.

Panelists drew attention to several key
issues the region faces in capitalizing on these
resources, with a focus on research and
development, financing, and education.
With respect to research and development,
effective technology transfer and translational
research will allow medical innovation to
evolve along the continuum from basic science
research to clinical care at the bedside. In
order for this to occur, partnerships between
academia and industry are essential. Funding
challenges include aligning incentives for
research and development, incentives for
investigators to pursue basic science research,
and defining the roles of public and private
funding sources. Finally, panelists indicated
that high quality education in the sciences
must begin in elementary school and continue
throughout higher education. Graduate
programs in the sciences must be able to
recruit young investigators and retain them
following graduation.
The event was co-hosted by America’s
biopharmaceutical companies, Pennsylvania BIO,
BioAdvance and Select Greater Philadelphia. 
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